Biogen Inc.
210.73USD
-1.7700 (-0.83%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 10.2B | 9.8B | 9.7B | 9.9B | 10.4B | 10.7B |
| Q1 | 2.5B | 2.5B | 2.3B | 2.4B | 2.5B | — |
| Q2 | 2.6B | 2.5B | 2.5B | 2.6B | — | — |
| Q3 | 2.5B | 2.5B | 2.5B | 2.5B | 2.6B | — |
| Q4 | 2.5B* | 2.4B* | 2.5B* | 2.3B* | 2.6B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 20.87 | 7.97 | 11.18 | 8.79 | 12.61 | 16.54 |
| Q1 | 2.06 | 2.67 | 2.70 | 1.64 | 2.15 | — |
| Q2 | 7.24 | 4.07 | 4.00 | 4.33 | — | — |
| Q3 | 7.84 | -.470 | 2.66 | 3.17 | 2.03 | — |
| Q4 | 3.77* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 1.71* |
| 1.83* |
| -.332* |
| 3.27 |
| — |